|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Immunological parameter | 1st line therapy patients | 2nd line therapy patients | p-value | Highest in:  |
| *% B cells* | 7.6±1 | 7.0±1.2 | ns |  |
| *% monocytes* | 23±2.6 | 28.5±3.5 | ns |  |
| *% CD4 T cells* | 34.1±2 | 34.8±4 | ns |  |
| *% CD8 T cells* | 22.1±1.9 | 15.9±2.2 | 0.045 | 1st |
| *Ratio CD4/CD8 T cells* | 1.7±0.2 | 2.5±0.4 | 0.07 | 2nd |
| *% CD27+ memory B cells* | 46.1±3.7 | 29.1±4 | 0.0059 | 1st |
| *% CD27- naïve B cells* | 52.8±4 | 70.9±4 | 0.0051 | 2nd |
| *Ratio naïve/memory B cells* | 1.28±0.2 | 3.17±0.6 | 0.0095 | 2nd |
| *% transitional T1 B cells* | 2.7±0.5 | 4.9±0.8 | 0.029 | 2nd |
| *% plasmablasts* | 26.7±3.2 | 14.9±2.4 | 0.0085 | 1st |
| *% plasma cells* | 1.4±0.21 | 1.13±0.13 | ns |  |
| *% CD27+IgD+ non-switched memory B cells* | 30.5±3.1 | 17.9±2.7 | 0.0068 | 1st |
| *% CD27-IgD- double negative B cells* | 5.2±0.6 | 5.6±1.6 | ns |  |
| *% CD25+ B cells* | 14.8±2.5 | 9.7±3.4 | ns |  |
| *% CD86+ B cells* | 13.9±2.4 | 6.1±2.2 | 0.026 | 1st |
| *% CD5+ B cells* | 28.5±3.7 | 38.4±6.8 | ns |  |
| *% IL10+ B cells* | 7.8±2,.7 | 0.9±0.29 | 0.019 | 1st |
| *% CD80+ B cells* | 16.4±3 | 13.5±2.6 | ns |  |
| *% CD1D+ B cells* | 28.3±7 | 30.7±7 | ns |  |
| *MFI IL10* | 93.6±7.4 | 132.1±4.9 | 0.0004 | 2nd |
| *MFI CD86+IL10* | 95.7±8.7 | 126.7±5.1 | 0.011 | 2nd |
| *MFI CD5+IL10* | 78.0±4.8 | 120.1±4.6 | 0.00002 | 2nd |
| *MFI CD80+IL10* | 88.7±6.2 | 131.7±6.7 | 0.0003 | 2nd |
| *MFI CD1D+IL10* | 89.1±6.1 | 127.1±5.1 | 0.0005 | 2nd |
| *MFI CD25+IL10* | 99.9±9.4 | 163.6±16 | 0.0055 | 2nd |
| *% CD69+ B cells* | 9.91±1.3 | 16.2±2.3 | 0.035 | 2nd |
| *MFI CD54* | 935±60 | 848±131 | ns |  |
| *MFI CD40* | 286±48 | 679±135 | 0.018 | 2nd |
| *MFI HLA-DR* | 2870±173 | 4223±921 | ns |  |
| *MFI BAFF-R* | 3213±252 | 4515±331 | 0.009 | 2nd |
| *MFI CD69* | 362±32 | 217±15 | 0.0013 | 1st |
| *% TGF+ B cells* | 2.63±0.28 | 2.46±0.36 | ns |  |
| *% IFN+ B cells* | 6.39±1.68 | 3.54±0,.5 | ns |  |
| *% TNF+ B cells* | 4.76±0.81 | 4.08±0.66 | ns |  |
| *% LT+ B cells* | 16.4±3.3 | 24.2±4.7 | ns |  |
| *% IL4+ B cells* | 2.42±0.54 | 3.02±0.73 | ns |  |
| *MFI TGF* | 224±25 | 272±40 | ns |  |
| *MFI IFN* | 451±92 | 398±31 | ns |  |
| *MFI TNF* | 160±34 | 168±7 | ns |  |
| *MFI LT* | 204±11 | 205±11 | ns |  |
| *MFI IL4* | 168±49 | 125±8 | ns |  |

**Table e-2 Baseline Immune profile of'1st' and '2nd line' patients**

Comparison of baseline values of various immune subsets and immunological markers. P-value between '1st' and '2nd line' patients calculated by Mann Whitney test or unpaired T-Test, according to normality of the data as assessed by Kolmogorov-Smirnov test. ns – non-significant. MFI- median fluorescence intensity.